CAS No. :	15826-37-6
Formula :	C₂₃H₁₄Na₂O₁₁
M.W :	512.33
SMILES Code :	OC(COC1=C2C(C=C(C([O-])=O)OC2=CC=C1)=O)COC3=C4C(C=C(C([O-])=O)OC4=CC=C3)=O.[Na+].[Na+]
Synonyms :	Disodium Cromoglycate; FPL-670; Cromolyn(sodium)
MDL No. :	MFCD22575281
InChI Key :	VLARUOGDXDTHEH-UHFFFAOYSA-L
Pubchem ID :	27503

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

BM-derived mouse mast cells	10 μM	30 minutes pretreatment, continued during coculture	Stabilize mast cells, reduce PDGF-A release and collagen expression	J Clin Invest. 2010 Jan;120(1):242-53.
HUVEC (human umbilical vein endothelial cells)	40 µM		Inhibition of mast cell degranulation, reducing FGF-2 secretion, thereby decreasing HUVEC proliferation and tube formation capacity	Nat Commun. 2017 Aug 16;8(1):269.
BxPC-3 cells	100 µM	24 hours	Cromolyn inhibited BxPC-3 cell invasiveness in a concentration-dependent manner	J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18.
Panc-1 cells	100 µM	24 hours	Cromolyn blocked the stimulatory effects of exogenous S100P on Panc-1 cell invasion	J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18.
BxPC-3 cells	100 µM	48 hours	Cromolyn inhibited BxPC-3 cell proliferation in a concentration-dependent manner	J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18.
Panc-1 cells	100 µM	48 hours	Cromolyn completely blocked the stimulatory effects of exogenous S100P on Panc-1 cell proliferation	J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18.

Mice	Mdr2−/− mice		24 mg/kg BW	1 week	Stabilization of mast cells, reducing intestinal mast cell infiltration, FXR and FGF15 expression	Hepatology. 2021 Nov;74(5):2684-2698
DBA/1 mice	Collagen-induced arthritis (CIA) model	Intraperitoneal injection	25 mg/kg	Administered every other day, starting from day 0	To evaluate the therapeutic effect of cromolyn on CIA, results showed combination therapy significantly reduced clinical severity and bone erosion	Nat Commun. 2024 Jan 2;15(1):113
Mice	Gp130FF mouse model	Intraperitoneal injection	75 mg/kg body weight	Three times per week for 6 consecutive weeks	To assess the therapeutic effect of Cromolyn on established tumors, results showed Cromolyn significantly reduced tumor burden	Nat Commun. 2019 Jun 21;10(1):2735
Mice	Pressure-overloaded heart model	Intraperitoneal injection	50 mg/kg/day	Once daily for 10 days	Stabilize mast cells, reduce atrial fibrosis and AF susceptibility	J Clin Invest. 2010 Jan;120(1):242-53.
Mice	Primary Sclerosing Cholangitis model	Osmotic minipumps	24 mg/kg/BW	1 week	To evaluate the effects of Cromolyn sodium on biliary proliferation and fibrosis in PSC model mice. Results showed that Cromolyn sodium treatment reduced biliary proliferation, fibrosis, histamine secretion, and bile flow.	Hepatology. 2016 Oct;64(4):1202-1216
C57BL/6J mice	Panc02 tumor model		25 mg/kg		Combination with anti-angiogenic therapy (DC101) enhanced anti-tumor and anti-angiogenic effects, reducing tumor vessel proliferation and tumor cell proliferation	Nat Commun. 2017 Aug 16;8(1):269.
CB17 scid mice	Orthotopic tumor models of BxPC-3, MPanc-96, and Panc-1 cells	Intraperitoneal injection	5 mg/kg body weight	Daily for 5 weeks	Cromolyn inhibited tumor growth in mice bearing tumors with endogenous S100P and increased the effectiveness of gemcitabine	J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18.
Mice	IFABPp-IL-9Tg mice	Intraperitoneal injection	100 mg/kg	Every 12 hours for 2.5 days	Stabilize mast cell activity, reduce intestinal permeability to HRP and FITC-dextran	J Exp Med. 2008 Apr 14;205(4):897-913

NCT00943397	-		Completed	-	-
NCT00123630	Esophagitis	Phase 2	Completed	-	United States, Utah ... More >> University of Utah HSC Salt Lake City, Utah, United States, 84132 Less <<
NCT00123630	-		Completed	-	-
NCT00943397	Asthma	Phase 3	Completed	-	-
NCT02482324	Healthy Volunteers	Phase 1	Completed	-	United States, Florida ... More >> Panax Clinical Research Miami Lakes, Florida, United States, 33014 Less <<
NCT02484248	Functional Dyspepsia	Phase 3	Recruiting	March 2025	United States, Missouri ... More >> The Children's Mercy Hospital Recruiting Kansas City, Missouri, United States, 64108 Contact: Amber Bagherian, MS 816-802-1176 abagherian@cmh.edu Principal Investigator: Craig A Friesen, MD Sub-Investigator: Jennifer Colombo, MD Sub-Investigator: Jennifer V Schurman, PhD Sub-Investigator: Amanda D Deacy, PhD Sub-Investigator: Susan Abdel-Rahman, PharmD Less <<
NCT02478957	Mastocytosis ... More >>Systemic Mastocytosis Indolent Systemic Mastocytosis Less <<	Phase 2	Completed	-	France ... More >> Hopital Necker - Enfants Malades Paris, France Germany Charité - Universitätsmedizin Berlin Berlin, Germany Klinikum Darmstadt Darmstadt, Germany University Medical Center Mainz Mainz, Germany Technical University München Munich, Germany Italy University of Salerno Salerno, Italy Netherlands University Medical Center of Groningen Groningen, Netherlands Spain Hospital Universitario de Fuenlabrada Madrid, Spain Less <<
NCT01346852	-		Completed	-	-
NCT01346852	-		Completed	-	-
NCT02547818	Alzheimer's Disease	Phase 3	Recruiting	November 2019	-
NCT02690935	Seasonal Allergy	Phase 4	Completed	-	Belgium ... More >> ResearchLink Linkebeek, Belgium, 1630 Less <<
NCT02690935	-		Completed	-	-
NCT02177370	Asthma	Phase 3	Terminated	-	-
NCT03167216	Chronic Prostatitis With Chron... More >>ic Pelvic Pain Syndrome Less <<	Early Phase 1	Recruiting	June 30, 2021	United States, Illinois ... More >> Northwestern Medical Faculty Foundation Recruiting Chicago, Illinois, United States, 60611 Principal Investigator: Praveen Thumbikat, PhD Less <<
NCT03202147	Ischemic Stroke ... More >> Post-stroke Cognitive Impairment Less <<	Phase 2	Suspended(Study halted prematu... More >>rely prior to initiation but potentially will resume) Less <<	-	-
NCT00777348	Asthma, Exercise-Induced	Phase 2	Completed	-	Germany ... More >> Kurmittelhaus der Moderne Bad Reichenhall, Germany, D-83435 Asthma Center Buchenhoehe Berchtesgaden, Germany, D-83471 Practice Dr. T. Ginko Bonn, Germany, D-53119 Clinic St. Georg Leipzig, Robert Koch Clinic Leipzig, Germany, D-04207 Clinical Research Pneumology, III. Medical Clinic, University Clinic Mainz Mainz, Germany, D-55131 Practice Dr. W. Schürmann Marburg, Germany, D-35037 Institute for Pulmonary Research GmbH Wiesbaden, Germany, D-65187 Less <<
NCT02664051	Dyspepsia	Phase 4	Unknown	February 2017	Belgium ... More >> Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Campus Gasthuisberg O&N1 Recruiting Leuven, Vlaams Brabant, Belgium, 3000 Contact: Hanne Vanheel +3216377524 hanne.vanheel@med.kuleuven.be Principal Investigator: Jan Tack, MD Less <<
NCT02566252	Healthy	Phase 1	Completed	-	United States, California ... More >> WCCT Global Cypress, California, United States, 90630 Less <<
NCT01175525	Acute Stroke	Phase 3	Unknown	-	Israel ... More >> Edith wolfson medical Center Not yet recruiting Holon, Israel, 58100 Contact: Lampl y_lampl@hotmail.com Less <<
NCT00745199	End Stage Renal Disease ... More >> Pruritus Less <<	Phase 2	Completed	-	Iran, Islamic Republic of ... More >> Shiraz University of Medical sciences, Nemazi and Faghihi Hospital Shiraz, Fars, Iran, Islamic Republic of, 71345 Less <<
NCT02131038	-		Completed	-	Germany ... More >> HNO Praxis Elmshorn Elmshorn, Germany Less <<
NCT01701843	Mastocytosis	Phase 2	Terminated(prematurely termina... More >>ted because of low recruitment) Less <<	-	Germany ... More >> Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin Berlin, Germany, D-10117 Less <<
NCT01933464	Papulopustular Rosacea	Phase 1 Phase 2	Unknown	-	United States, California ... More >> UCSD Division of Dermatology Recruiting San Diego, California, United States, 92122 Contact: Aimee Two, MD 858-657-8390 ucsddermstudies@gmail.com Principal Investigator: Anna Di Nardo, MD, PhD Less <<
NCT01841307	Gastroesophageal Reflux ... More >> Respiratory Aspiration Idiopathic Pulmonary Fibrosis Lung Transplantation Less <<	Phase 1	Unknown	July 2017	United States, California ... More >> UCSF Airway Clinical Research Center Recruiting San Francisco, California, United States, 94143 Contact: Andrew M Manies, A.B. 415-353-1210 andrew.manies@ucsf.edu Contact: Julian Silva 415-476-5418 julian.silva@ucsf.edu Principal Investigator: Homer A Boushey, M.D. Less <<
NCT02371941	Eosinophilic Esophagitis	Phase 4	Completed	-	United States, Tennessee ... More >> LeBonheur Children's Hospital Memphis, Tennessee, United States, 38105 Less <<
NCT01722812	Psoriasis	Phase 2	Completed	-	Germany ... More >> Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin Berlin, Germany, D-10117 Less <<

{[proInfo.proName]}

CAS No.: 15826-37-6

{[proInfo.proName]}

CAS No.: 15826-37-6

Alternative Products

Product Details of Cromolyn sodium

Safety of Cromolyn sodium

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.95mL 0.39mL 0.20mL	9.76mL 1.95mL 0.98mL	19.52mL 3.90mL 1.95mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2 The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed